901 related articles for article (PubMed ID: 28919200)
1. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
2. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
4. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
5. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
6. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
7. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
DuBuske L; Newbold P; Wu Y; Trudo F
Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
9. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Sproule S; Olsson RF; Martin UJ; Goldman M;
Lancet Respir Med; 2019 Jan; 7(1):46-59. PubMed ID: 30416083
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
12. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
13. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
[TBL] [Abstract][Full Text] [Related]
14. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.
Bleecker ER; Wechsler ME; FitzGerald JM; Menzies-Gow A; Wu Y; Hirsch I; Goldman M; Newbold P; Zangrilli JG
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139780
[TBL] [Abstract][Full Text] [Related]
15. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
16. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
[TBL] [Abstract][Full Text] [Related]
18. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
[TBL] [Abstract][Full Text] [Related]
20. Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.
Lugogo NL; Kreindler JL; Martin UJ; Cook B; Hirsch I; Trudo FJ
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):171-176. PubMed ID: 32334141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]